Indegene, the global life sciences tech services company, has announced the acquisition of Pennsylvania-based BioPharm Communications for USD 106 million. This deal strengthens Indegene’s commercial capabilities by combining its data, analytics and AI platforms with BioPharm’s expertise in omnichannel marketing, media strategy and precision engagement with healthcare providers.

BioPharm, prior to the acquisition, was part of the Omnicom Health Group and offers services to many leading biopharma clients, crafting targeted campaigns and insights tools for market outreach. With this integration, Indegene expects to enhance its product offerings in ad-tech, amplify media return on investment, and deliver more refined campaign outcomes for its pharmaceutical customers.

Manish Gupta, Chair and CEO of Indegene, commented that the acquisition reinforces the company’s positioning as a “tech-native” commercialisation partner for the life sciences sector, especially in an era where digital transformation and AI adoption are redefining how pharma engages with stakeholders.

This move comes at a time of evolving market dynamics, including increasing trade and regulatory pressures, where having stronger North American presence and integrated digital capabilities are seen as strategic advantages.